| 0 (0%) | 09-27 11:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 209.17 |
1-year : | 219.08 |
| Resists | First : | 179.08 |
Second : | 187.57 |
| Pivot price | 177.78  |
|||
| Supports | First : | 165.36 |
Second : | 137.58 |
| MAs | MA(5) : | 175.26 |
MA(20) : | 177.38 |
| MA(100) : | 153.08 |
MA(250) : | 117.49 |
|
| MACD | MACD : | 2.2 |
Signal : | 4.1 |
| %K %D | K(14,3) : | 17 |
D(3) : | 28.8 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 187.57 | Low : | 55.91 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRTC ] has closed above bottom band by 16.5%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 172.6 - 173.8 | 173.8 - 174.73 |
| Low: | 165.82 - 167.46 | 167.46 - 168.72 |
| Close: | 168.53 - 170.76 | 170.76 - 172.47 |
Wed, 24 Sep 2025
How Investors May Respond To iRhythm Technologies (IRTC) Securities Lawsuit Advancing After FDA Non-Conformity Findings - simplywall.st
Tue, 23 Sep 2025
Evercore ISI Group Initiates Coverage of iRhythm Technologies (IRTC) with In-Line Recommendation - Nasdaq
Tue, 23 Sep 2025
Evercore ISI Group Initiates Coverage on iRhythm Technologies (I - GuruFocus
Tue, 23 Sep 2025
Evercore Initiates IRhythm Technologies(IRTC.US) With Hold Rating, Announces Target Price $185 - 富途牛牛
Mon, 22 Sep 2025
A Look at iRhythm Technologies’s Valuation Following FDA Warning and Securities Lawsuit Progress - simplywall.st
Tue, 16 Sep 2025
iRhythm: Getting Closer To Investment Worthy (NASDAQ:IRTC) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 32 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 112.4 (%) |
| Shares Short | 2,780 (K) |
| Shares Short P.Month | 2,520 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | -14.1 % |
| Operating Margin | -5.8 % |
| Return on Assets (ttm) | -3.6 % |
| Return on Equity (ttm) | -91.2 % |
| Qtrly Rev. Growth | 26.1 % |
| Gross Profit (p.s.) | 14.27 |
| Sales Per Share | 20.45 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 63 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | -58.5 |
| PEG Ratio | 0 |
| Price to Book value | 52.88 |
| Price to Sales | 8.35 |
| Price to Cash Flow | 86.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|